We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Read MoreHide Full Article
Key Takeaways
Keytruda sales were $23.3B in the first nine months of 2025, up 8% Y/Y, anchoring MRK's revenue growth.
MRK said Q3 Keytruda sales were softer due to channel movements, not weaker demand, with focus on Q4.
MRK expects continued Keytruda growth from earlier-stage and metastatic use, aided by a new SC formulation.
A meaningful portion of Merck’s (MRK - Free Report) revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical revenues. Keytruda has played an instrumental role in driving Merck’s steady revenue growth over the past few years, with sales of $23.3 billion in the first nine months of 2025 representing an 8% year-over-year increase.
Though Keytruda sales increased 8% year over year during the third quarter of 2025, they were weaker than expected. Per management, Keytruda's soft sales in the third quarter were due to unfavorable channel movements and not due to a drop in underlying demand. Building on this optimism, we expect investors to focus on the sales performance of Keytruda when Merck reports its fourth-quarter and full-year 2025 results on Feb. 3.
Keytruda sales are likely to have gained from rapid uptake across earlier-stage indications and strong momentum in metastatic indications in the fourth quarter. The company expects continued growth from Keytruda, particularly in the early lung cancer indication.
The Zacks Consensus Estimate for Keytruda’s fourth-quarter sales stands at $8.27 billion, while our model estimate is $8.21 billion.
In 2026, Merck expects Keytruda to grow and expand into new indications and markets globally continuously, as the FDA decision for ovarian cancer, as well as other cancer indications, draws closer. Keytruda is not approved to treat ovarian cancer.
Also, the recent FDA approval for the subcutaneous (SC) formulation of Keytruda, known as Keytruda Qlex, which improves patient convenience, is likely to aid sales further.
PD-L1 Inhibitors Competing With Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $7.35 billion in Opdivo sales during the first nine months of 2025, up 8% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 2.61 billion in Tecentriq sales in the first nine months of 2025.
AZN’s Imfinzi generated sales of $4.32 billion in the first nine months of 2025, up 25%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
MRK's Price Performance, Valuation and Estimates
Over the past six months, shares of Merck have rallied 32.8%, compared with the industry’s 23.2% rise. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 12.83 forward earnings, lower than 17.81 for the industry but higher than its 5-year mean of 12.48.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has remained stable at $8.97, while the same for 2026 has decreased from $9.33 to $7.94 over the past 60 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #5 (Strong Sell).
Image: Bigstock
Will Keytruda Continue to Aid Merck's Top Line in Q4 Earnings?
Key Takeaways
A meaningful portion of Merck’s (MRK - Free Report) revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, Keytruda. The drug contributes over half of the company’s pharmaceutical revenues. Keytruda has played an instrumental role in driving Merck’s steady revenue growth over the past few years, with sales of $23.3 billion in the first nine months of 2025 representing an 8% year-over-year increase.
Though Keytruda sales increased 8% year over year during the third quarter of 2025, they were weaker than expected. Per management, Keytruda's soft sales in the third quarter were due to unfavorable channel movements and not due to a drop in underlying demand. Building on this optimism, we expect investors to focus on the sales performance of Keytruda when Merck reports its fourth-quarter and full-year 2025 results on Feb. 3.
Keytruda sales are likely to have gained from rapid uptake across earlier-stage indications and strong momentum in metastatic indications in the fourth quarter. The company expects continued growth from Keytruda, particularly in the early lung cancer indication.
The Zacks Consensus Estimate for Keytruda’s fourth-quarter sales stands at $8.27 billion, while our model estimate is $8.21 billion.
In 2026, Merck expects Keytruda to grow and expand into new indications and markets globally continuously, as the FDA decision for ovarian cancer, as well as other cancer indications, draws closer. Keytruda is not approved to treat ovarian cancer.
Also, the recent FDA approval for the subcutaneous (SC) formulation of Keytruda, known as Keytruda Qlex, which improves patient convenience, is likely to aid sales further.
PD-L1 Inhibitors Competing With Keytruda
Keytruda faces competition from other PD-L1 inhibitors, including Bristol Myers’ (BMY - Free Report) Opdivo, Roche’s (RHHBY - Free Report) Tecentriq and AstraZeneca’s (AZN - Free Report) Imfinzi.
BMY’s Opdivo, like Keytruda, is approved across multiple cancer types, including lung, melanoma and kidney cancers. Bristol Myers recorded $7.35 billion in Opdivo sales during the first nine months of 2025, up 8% year over year.
Tecentriq is Roche’s leading immuno-oncology drug approved for multiple cancer indications. RHHBY recorded CHF 2.61 billion in Tecentriq sales in the first nine months of 2025.
AZN’s Imfinzi generated sales of $4.32 billion in the first nine months of 2025, up 25%, driven by demand growth in lung and liver cancer indications. Imfinzi has strategically expanded its use across multiple cancer indications, strengthening AstraZeneca’s oncology portfolio.
MRK's Price Performance, Valuation and Estimates
Over the past six months, shares of Merck have rallied 32.8%, compared with the industry’s 23.2% rise. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 12.83 forward earnings, lower than 17.81 for the industry but higher than its 5-year mean of 12.48.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has remained stable at $8.97, while the same for 2026 has decreased from $9.33 to $7.94 over the past 60 days.
Image Source: Zacks Investment Research
MRK's Zacks Rank
Merck currently has a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.